Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 20

1.

Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states.

Cohn RD, van Erp C, Habashi JP, Soleimani AA, Klein EC, Lisi MT, Gamradt M, ap Rhys CM, Holm TM, Loeys BL, Ramirez F, Judge DP, Ward CW, Dietz HC.

Nat Med. 2007 Feb;13(2):204-10. Epub 2007 Jan 21. Erratum in: Nat Med. 2007 Apr;13(4):511.

2.

Recent advances in understanding Marfan syndrome: should we now treat surgical patients with losartan?

Matt P, Habashi J, Carrel T, Cameron DE, Van Eyk JE, Dietz HC.

J Thorac Cardiovasc Surg. 2008 Feb;135(2):389-94. doi: 10.1016/j.jtcvs.2007.08.047. Review.

3.

Pathophysiology and Management of Cardiovascular Manifestations in Marfan and Loeys-Dietz Syndromes.

Takeda N, Yagi H, Hara H, Fujiwara T, Fujita D, Nawata K, Inuzuka R, Taniguchi Y, Harada M, Toko H, Akazawa H, Komuro I.

Int Heart J. 2016 May 25;57(3):271-7. doi: 10.1536/ihj.16-094. Epub 2016 May 13. Review.

4.

Recent progress towards a molecular understanding of Marfan syndrome.

Dietz HC, Loeys B, Carta L, Ramirez F.

Am J Med Genet C Semin Med Genet. 2005 Nov 15;139C(1):4-9. Review.

PMID:
16273535
5.

[Molecular biological aspects of Marfan syndromes].

Belsing TZ, Lund AM, Abildstrøm SZ, Søndergaard L, Friis-Hansen L.

Ugeskr Laeger. 2011 Jan 31;173(5):333-7. Review. Danish.

PMID:
21276395
6.

[Novel pharmacological strategies for aortic dilation in Marfan syndrome: from mouse models to human patients].

Perrino C, Schiattarella GG, Bottino R, Magliulo F, Oliveti M, Esposito G, Trimarco B.

G Ital Cardiol (Rome). 2014 Jul-Aug;15(7-8):408-17. doi: 10.1714/1596.17416. Review. Italian.

PMID:
25174594
7.
8.

[Interactions between fibrillin-1 and tgf-beta: consequences and human pathology].

Wipff J, Allanore Y, Boileau C.

Med Sci (Paris). 2009 Feb;25(2):161-7. doi: 10.1051/medsci/2009252161. Review. French.

9.

Drug-based therapies for vascular disease in Marfan syndrome: from mouse models to human patients.

Cook JR, Nistala H, Ramirez F.

Mt Sinai J Med. 2010 Jul-Aug;77(4):366-73. doi: 10.1002/msj.20200. Review.

10.

Angiotensin receptor blockers: a panacea for Marfan syndrome and related disorders?

Loeys BL.

Drug Discov Today. 2015 Feb;20(2):262-6. doi: 10.1016/j.drudis.2014.09.022. Epub 2014 Oct 2. Review.

PMID:
25281853
11.

Molecular genetics of Marfan syndrome.

Boileau C, Jondeau G, Mizuguchi T, Matsumoto N.

Curr Opin Cardiol. 2005 May;20(3):194-200. Review.

PMID:
15861007
12.

[Molecular mechanism and therapeutic strategy for cerebral small vessel disease].

Hara K.

Rinsho Shinkeigaku. 2010 Nov;50(11):852-4. Review. Japanese.

PMID:
21921470
13.

Recent progress in genetics of Marfan syndrome and Marfan-associated disorders.

Mizuguchi T, Matsumoto N.

J Hum Genet. 2007;52(1):1-12. Epub 2006 Oct 24. Review.

PMID:
17061023
14.

Latent transforming growth factor-beta binding proteins (LTBPs)--structural extracellular matrix proteins for targeting TGF-beta action.

Saharinen J, Hyytiäinen M, Taipale J, Keski-Oja J.

Cytokine Growth Factor Rev. 1999 Jun;10(2):99-117. Review.

PMID:
10743502
15.

The role of transforming growth factor-beta in Marfan syndrome.

Benke K, Ágg B, Szilveszter B, Tarr F, Nagy ZB, Pólos M, Daróczi L, Merkely B, Szabolcs Z.

Cardiol J. 2013;20(3):227-34. doi: 10.5603/CJ.2013.0066. Review.

16.

Connective tissue disorders and cardiovascular complications: the indomitable role of transforming growth factor-beta signaling.

Wheeler JB, Ikonomidis JS, Jones JA.

Adv Exp Med Biol. 2014;802:107-27. doi: 10.1007/978-94-007-7893-1_8. Review.

17.

Bone lessons from Marfan syndrome and related disorders: fibrillin, TGF-B and BMP at the balance of too long and too short.

Loeys BL, Mortier G, Dietz HC.

Pediatr Endocrinol Rev. 2013 Jun;10 Suppl 2:417-23. Review.

PMID:
23858625
18.

Modifying muscular dystrophy through transforming growth factor-β.

Ceco E, McNally EM.

FEBS J. 2013 Sep;280(17):4198-209. doi: 10.1111/febs.12266. Epub 2013 Apr 24. Review.

19.

Biological approaches to improve skeletal muscle healing after injury and disease.

Gharaibeh B, Chun-Lansinger Y, Hagen T, Ingham SJ, Wright V, Fu F, Huard J.

Birth Defects Res C Embryo Today. 2012 Mar;96(1):82-94. doi: 10.1002/bdrc.21005. Review.

20.

TGF-β signalopathies as a paradigm for translational medicine.

Cannaerts E, van de Beek G, Verstraeten A, Van Laer L, Loeys B.

Eur J Med Genet. 2015 Dec;58(12):695-703. doi: 10.1016/j.ejmg.2015.10.010. Epub 2015 Oct 24. Review.

PMID:
26598797

Supplemental Content

Support Center